Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes

Study acronym: ARC
StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 31 days later Aug 2038 → Oct 2038
See other at-risk trials from Ataraxis AI, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 31, 2026 to Oct 31, 2026
    • Primary completion pushed from Aug 2038 to Oct 2038
    • Eligibility criteria expanded, about 7 words
    • Study description expanded, about 3 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will link Ataraxis test results with short- and long-term patient outcomes to evaluate the real-world performance and clinical utility of Ataraxis tests. The ARC Registry utilizes an adaptable design, where additional Sponsor-led analyses and investigator-initiated ancillary studies can be added after the initial study is opened.
Trial Details
NCT Number NCT07706842
Lead Sponsor Ataraxis AI, Inc.
Conditions
(from sponsor)		 Solid Tumor Malignancy, Breast Cancer
Related terms Breast Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov